3 active not recruiting, 2 completed, 1 recruiting. 4 Phase 2, 2 Phase 3.
By phase and status
Follow crinecerfont: new trials by email Literature Review of crinecerfont trials Research Report on crinecerfont
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Crinecerfont - Congenital Adrenal Hyperplasia | Phase 2 | Recruiting | Neurocrine Switzerland GmbH | 20 | 2026-07-01 | 2026-09-16 |
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Crinecerfont - Congenital Adrenal Hyperplasia | Phase 2 | Active not recruiting | Neurocrine Switzerland GmbH | 7 | 2025-09-30 | 2026-08-28 |
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Crinecerfont, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Active not recruiting | Neurocrine Biosciences | 103 | 2021-06-25 | 2025-02-05 |
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Crinecerfont, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Active not recruiting | Neurocrine Biosciences | 182 | 2020-12-16 | 2026-05-11 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
Crinecerfont - CAH - Congenital Adrenal Hyperplasia | Phase 2 | Completed | Neurocrine Biosciences | 8 | 2019-12-12 | 2024-07-18 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
NBI-74788 - CAH - Congenital Adrenal Hyperplasia | Phase 2 | Completed | Neurocrine Biosciences | 18 | 2018-04-10 | 2022-05-03 |
Conditions studied
Adrenal Hyperplasia, Congenital (6) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (1)
Sponsors
Neurocrine Biosciences (4) · Neurocrine Switzerland GmbH (2)
Countries
United States (5) · Germany (3) · Belgium (2) · Canada (2) · France (2) · Greece (2) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · Austria (1) · Bulgaria (1) · Czechia (1) · Israel (1) · Netherlands (1)
Results publications
PMID 37216921, PMID 38828945, PMID 38828955
NIH funding
2023 (2), 2019 (1)